Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

scientific article published on 12 June 2006

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/505210
P698PubMed publication ID16779754

P50authorAmmarin ThakkinstianQ47152142
Kiat RuxrungthamQ66733145
P2093author name stringSomnuek Sungkanuparph
Weerawat Manosuthi
Sirirat Likanonsakul
Wisit Prasithsirikul
Sasivimol Rattanasiri
Achara Chaovavanich
P433issue2
P921main subjectnevirapineQ263713
rifampicinQ422652
P304page(s)253-255
P577publication date2006-06-12
P1433published inClinical Infectious DiseasesQ5133764
P1476titlePlasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin
P478volume43

Reverse relations

cites work (P2860)
Q55417509Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia.
Q26991633Diagnosis & treatment of tuberculosis in HIV co-infected patients
Q24609011Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all
Q33375532Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study
Q36576089Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda
Q34571594Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings
Q35530299Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand
Q37390235HIV and tuberculosis in India
Q34710641Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
Q59650851Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial
Q47102399Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
Q52330065Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.
Q33364134Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Q35689833Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.
Q37227388Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana
Q35571505The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment
Q30658709The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review
Q36688887Tuberculosis and HIV co-infection: a practical therapeutic approach

Search more.